References
- Fox KE. Management of heavy menstrual bleeding in general practice. Curr Med Res Opin. 2012;28:1517–1525.
- Liu Z, Doan QV, Blumenthal P, et al. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health. 2007;10:183–194.
- Dioguardi M, Caloro GA, Troiano G, et al. Oral manifestations in chronic uremia patients. Ren Fail. 2016;38:1–6.
- Lin CT, Liu XN, Xu HL, et al. Menstrual disturbances in premenopausal women with end-stage renal disease: a cross-sectional study. Med Princ Pract. 2016;25:260–265.
- Munro MG. Endometrial ablation. Best Pract Res Clin Obstet Gynaecol. 2018;46:120–139.
- Gimpelson RJ. Ten-year literature review of global endometrial ablation with the NovaSure(R) device. Int J Women's Health. 2014;6:269–280.
- Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol. 1995;85:977–982.
- Cooper J, Gimpelson R, Laberge P, et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. J Am Ass Gynecol Laparosc. 2002;9:418–428.
- Trkulja V. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices. Med Hypotheses. 2012;78:157–161.
- Anderson GD, Odegard PS. Pharmacokinetics of estrogen and progesterone in chronic kidney disease. Adv Chronic Kidney Dis. 2004;11:357–360.
- Kovic SV, Vujovic KS, Srebro D, et al. Prevention of renal complications induced by non- steroidal anti-inflammatory drugs. Curr Med Chem. 2016;23:1953–1964.
- Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009;8:669–681.
- Wong JMK, Bortoletto P, Tolentino J, et al. Urinary tract injury in gynecologic laparoscopy for benign indication: a systematic review. Obstet Gynecol. 2017;131:1–108.
- Kahr HS, Thorlacius-Ussing O, Christiansen OB, et al. Venous thromboembolic complications to hysterectomy for benign disease: a nationwide cohort study. J Minim Invasive Gynecol. 2018;25:715–723.
- Asgari Z, Moini A, Samiee H, et al. Endometrial ablation with the NovaSure system in Iran. Int J Gynaecol Obstet. 2011;114:73–75.
- Gallinat A. An impedance-controlled system for endometrial ablation: five-year follow-up of 107 patients. J Reprod Med. 2007;52:467–472.
- Bongers MY, Bourdrez P, Mol BW, et al. Randomised controlled trial of bipolar radio-frequency endometrial ablation and balloon endometrial ablation. BJOG. 2004;111:1095–1102.
- Kleijn JH, Engels R, Bourdrez P, et al. Five-year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. BJOG. 2007;115:193–198.
- Clark TJ, Samuels N, Malick S, et al. Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office: a randomized controlled trial. Obstet Gynecol. 2011;117:1228.
- Gallinat A, Nugent W. NovaSure impedance-controlled system for endometrial ablation. J Am Ass Gynecol Laparosc. 2002;9:283–289.
- Kalkat RK, Cartmill RS. NovaSure endometrial ablation under local anaesthesia in an outpatient setting: an observational study. J Obstet Gynaecol. 2011;31:152–155.
- Baskett TF, Clough H, Scott TA. NovaSure bipolar radiofrequency endometrial ablation: report of 200 cases. J Obstet Gynaecol. 2005;27:473–476.
- Moulder JK, Yunker A. Endometrial ablation: considerations and complications. Curr Opin Obstet Gynecol. 2016;28:261–266.